The US Food and Drug Administration issued warning letters today to five companies illegally selling products containing cannabidiol (CBD).
Several companies have been accused of selling products containing CBD. The FDA has stated that some consumers may confuse these products with traditional food and beverages that do not contain CBD, which could lead to unintended or excessive consumption of CBD.
The FDA expressed concern in a press release about CBD-containing products that appeal to children, such as gummies, hard candies, and cookies.
On November 11th, BrandsNaturally Infused LLC, Newhere Inc. dba CBDFX, Infusionz LLC, and CBD American Shaman, LLC, all received warning letters from an undisclosed sender.
According to the agency, the FDA has yet to find sufficient information to determine how much CBD can be consumed and for how long before it causes harm.
The organization stated that this is particularly important for vulnerable groups such as children and pregnant women. People should be aware of the potential risks associated with using CBD products.
The warning letter also outlined other violations of the Food, Drug, and Cosmetic Act, including some companies illegally selling CBD products that claim to cure, alleviate, treat, or prevent various diseases without approval and adding CBD to animal food, such as pet snacks.
The FDA has required these companies to respond within 15 business days, outlining how they plan to address the issues described in the warning letter, or providing reasoning and supporting information for why they believe their products are not in violation of the law," the agency wrote. "Failing to promptly and adequately address noncompliance may result in legal action, including product seizure and/or injunction.
Statement:
This article is compiled from information from third-party sources and is only intended for industry professionals for learning and exchange purposes.
This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The translation of this article is intended solely for communication and research within the industry.
Due to limitations in translation skills, the translated article may not fully express the same meaning as the original. Please refer to the original article for accuracy.
2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong/Macao/Taiwan-related, and foreign statements and positions.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to remove it.
This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.
